If you need help accessing our website, call 855-698-9991
Skip to main content
Affiliated Provider
Affiliated providers provide medical care at an NYU Langone location or a private practice, and are not employed by NYU Langone Health.

Jonathan D. Brodie, MD, PhD

Affiliated Provider
Affiliated providers provide medical care at an NYU Langone location or a private practice, and are not employed by NYU Langone Health.
  • Specialty: Psychiatry
  • Treats: Adults
  • Language: English
  • Phone: 212-986-6693
View Locations

Board Certifications
  • American Board of Psychiatry & Neurology - Psychiatry, 1979
Education and Training
  • Residency, NYU Medical Center, Psychiatry, 1978
  • MD from New York University, 1975
  • PhD from University Of Wisconsin, 1962

Is this your profile?

Edit profile

This provider accepts the following insurance plans.

This list of insurances changes regularly, and insurance plans listed may not be accepted at all office locations for this provider. Before your appointment, please confirm with your insurance company that this provider accepts your insurance.

Jonathan D. Brodie, MD, PhD does not accept insurance.

Locations and Appointments

155 East 38 Street, New York, NY 10016






functional neuroimaging of pharmacological activity, relationship of neural plasticity to the emergence of psychopathology

Research Summary

For many years, Dr. Brodie has maintained a close collaboration with Dr. Stephen Dewey and the PET group of Brookhaven National Laboratory. This effort has focused on the investigation of neurotransmitter interactions and their application to clinical issues. We use PET neuroimaging methods with pharmacological perturbations as probes and changes in binding of radioligands to specific neuroreceptors as outcome measures. We pair these human and non-human primate studies with microdialysis studies and behavioral observations as independent measures. With this strategy, we have established that the hallmark of any functioning psychoactive drug is chemical plasticity, expressed as neurotransmitter interactions, i.e. the ability to transmit and transduce a chemical signal to brain regions that may be distinguished in space and/or time. We are actively investigating the complexity of this accommodation with pharmacologic probes in non-human primates, normal controls and patient populations. Measurement of these interactions with PET is now an accepted method for examining pharmacological activity in vivo. Initially, we developed probes to investigate the ability of one neurotransmitter to modulate or be modulated by another functionally linked neurotransmitter system by using multiple radiotracers and pharmacologically specific challenges in the study of schizophrenia. These early studies have since evolved to encompass such areas as neuroleptic response and neurotransmitter stability. More recently our studies of GABAergic modulation of dopamine have led to the exciting findings that the suicide inhibitor of GABA transaminase, GVG, is an extraordinarily effective drug in blocking the use of virtually all drugs of abuse, including cocaine, nicotine, heroin, alcohol, methamphetamine and others. We are actively involved in the extension of these studies to human patients.

These focus areas and their associated publications are derived from PubMed and the MeSH term library. *
represents one publication
*Due to PubMed processing times, the most recent publications may not be reflected in the timeline.

Read All Publications (134)